Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma

PURPOSE: Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established. MATERIALS AND METHODS: Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institution...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Yongjun, Kim, Yu Jung, Lee, Se-Hoon, Kim, Tae-Min, Choi, Seung Hong, Kim, Dong-Wan, Park, Chul-Kee, Kim, Il Han, Kim, Jee Hyun, Kim, Eunhee, Choi, Byungse, Kim, Chae-Yong, Kim, In Ah, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266387/
https://www.ncbi.nlm.nih.gov/pubmed/27188199
http://dx.doi.org/10.4143/crt.2015.466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266387/
https://www.ncbi.nlm.nih.gov/pubmed/27188199
http://dx.doi.org/10.4143/crt.2015.466

Ejemplares similares